Results 221 to 230 of about 197,154 (267)
Some of the next articles are maybe not open access.
Hematology, 2023
Abstract Immune checkpoint inhibitors are a class of antineoplastic therapies that unleash immune cells to kill malignant cells. These medications commonly cause immune-related adverse effects due to activated adaptive and innate immune cells, autoantibody production, and/or cytokine dysregulation.
openaire +2 more sources
Abstract Immune checkpoint inhibitors are a class of antineoplastic therapies that unleash immune cells to kill malignant cells. These medications commonly cause immune-related adverse effects due to activated adaptive and innate immune cells, autoantibody production, and/or cytokine dysregulation.
openaire +2 more sources
Immune Checkpoint Inhibitors in Melanoma [PDF]
Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and anti-PD-1 antibodies, have revolutionised the management of many cancers, particularly advanced melanoma, for which tumour regression and long-term durable cancer control ...
James Larkin, Georgina V. Long
exaly +3 more sources
Immune checkpoint inhibitors and vasculitis
Current Opinion in Rheumatology, 2020Purpose of review Clinical use of immune checkpoint inhibitor (ICI) therapy has revolutionized the therapeutic landscape of cancer. By activating the immune system using monoclonal anti-CTLA-4 and PD(L)-1 antibodies, remission can be induced in previously terminal cancers. However, these breakthroughs come at a price.
Patrick, Boland +2 more
openaire +2 more sources
Immune Checkpoint Inhibitors in the Aged
Current Oncology Reports, 2021Large phase III trials have established the benefit of checkpoint blockade across multiple tumor types, but patient representation is limited in some subgroups including the aged population. There are several changes in the immune system that occur with age (termed immunosenescence) that could potentially limit efficacy in aged populations.Despite the ...
James Isaacs +2 more
openaire +2 more sources
Resistance mechanisms to checkpoint inhibitors
Current Opinion in Immunology, 2021Although multiple immune checkpoint inhibitors (ICI) have been identified and tested in the clinic, antibodies blocking the PD-1/PD-L1 axis have produced the greatest impact on cancer treatment. Many potential mechanisms of treatment failure have been proposed from pre-clinical animal and human translational studies.
Sarah A, Weiss, Mario, Sznol
openaire +2 more sources
2015
Undoubtedly the discovery of immune checkpoints such as CTLA-4 and PD-1 has been crucial to the development of cancer immunotherapy. Although these molecules were originally discovered as molecules playing a role in T cell activation or apoptosis, subsequent preclinical research showed their important role in the maintenance of peripheral immune ...
John B A G, Haanen, Caroline, Robert
openaire +2 more sources
Undoubtedly the discovery of immune checkpoints such as CTLA-4 and PD-1 has been crucial to the development of cancer immunotherapy. Although these molecules were originally discovered as molecules playing a role in T cell activation or apoptosis, subsequent preclinical research showed their important role in the maintenance of peripheral immune ...
John B A G, Haanen, Caroline, Robert
openaire +2 more sources

